Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 330Breast Neoplasms 185Lung Neoplasms 177Ovarian Neoplasms 156Triple Negative Breast Neoplasms 88Fallopian Tube Neoplasms 75Squamous Cell Carcinoma of Head and Neck 74Small Cell Lung Carcinoma 67Esophageal Neoplasms 55Neoplasms 49Head and Neck Neoplasms 47Carcinoma, Ovarian Epithelial 44Uterine Cervical Neoplasms 36Esophageal Squamous Cell Carcinoma 36Endometrial Neoplasms 35Prostatic Neoplasms 33Neoplasm Metastasis 32Lymphoma, Large B-Cell, Diffuse 32Recurrence 31Adenocarcinoma of Lung 31Lymphoma 30Brain Neoplasms 29Neuroblastoma 24Central Nervous System Neoplasms 24Retinoblastoma 23Lymphoma, Non-Hodgkin 23Carcinoma, Squamous Cell 23Hodgkin Disease 20Testicular Neoplasms 19Urinary Bladder Neoplasms 16

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Resectable Esophageal Cancer × Carboplatin × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡